[PDF][PDF] Integrative clinical genomics of advanced prostate cancer
Toward development of a precision medicine framework for metastatic, castration-resistant
prostate cancer (mCRPC), we established a multi-institutional clinical sequencing …
prostate cancer (mCRPC), we established a multi-institutional clinical sequencing …
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
GM Frampton, A Fichtenholtz, GA Otto, K Wang… - Nature …, 2013 - nature.com
As more clinically relevant cancer genes are identified, comprehensive diagnostic
approaches are needed to match patients to therapies, raising the challenge of optimization …
approaches are needed to match patients to therapies, raising the challenge of optimization …
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer
Prostate cancer is the second most common cancer in men worldwide and causes over
250,000 deaths each year. Overtreatment of indolent disease also results in significant …
250,000 deaths each year. Overtreatment of indolent disease also results in significant …
[PDF][PDF] Organoid cultures derived from patients with advanced prostate cancer
The lack of in vitro prostate cancer models that recapitulate the diversity of human prostate
cancer has hampered progress in understanding disease pathogenesis and therapy …
cancer has hampered progress in understanding disease pathogenesis and therapy …
[HTML][HTML] Punctuated evolution of prostate cancer genomes
The analysis of exonic DNA from prostate cancers has identified recurrently mutated genes,
but the spectrum of genome-wide alterations has not been profiled extensively in this …
but the spectrum of genome-wide alterations has not been profiled extensively in this …
Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer
An increasingly recognized resistance mechanism to androgen receptor (AR)-directed
therapy in prostate cancer involves epithelial plasticity, in which tumor cells demonstrate low …
therapy in prostate cancer involves epithelial plasticity, in which tumor cells demonstrate low …
Genomic correlates of clinical outcome in advanced prostate cancer
Heterogeneity in the genomic landscape of metastatic prostate cancer has become apparent
through several comprehensive profiling efforts, but little is known about the impact of this …
through several comprehensive profiling efforts, but little is known about the impact of this …
Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine
Precision medicine is an approach that takes into account the influence of individuals'
genes, environment, and lifestyle exposures to tailor interventions. Here, we describe the …
genes, environment, and lifestyle exposures to tailor interventions. Here, we describe the …
Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing
A 44-year old woman with recurrent solitary fibrous tumor (SFT)/hemangiopericytoma was
enrolled in a clinical sequencing program including whole-exome and transcriptome …
enrolled in a clinical sequencing program including whole-exome and transcriptome …
TMPRSS2: ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort
F Demichelis, K Fall, S Perner, O Andrén, F Schmidt… - Oncogene, 2007 - nature.com
The identification of the TMPRSS2: ERG fusion in prostate cancer suggests that distinct
molecular subtypes may define risk for disease progression. In surgical series, TMPRSS2 …
molecular subtypes may define risk for disease progression. In surgical series, TMPRSS2 …